Listenly

How much did Illumina's sequencing cost per human genome decline from 2010 to 2021?

Answered at 18:58 in Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing

— questions searchable right now

How much did Illumina's sequencing cost per human genome decline from 2010 to 2021?

Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021. Despite this massive cost reduction, Illumina's revenue actually increased from $1 billion to $4.5 billion because applications and volumes of gene sequencing exploded higher, enabled by the greater affordability.

Unknown on Intrinsic InvestingAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021.

Guest · Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing · answer at 18:58

Key takeaways

  • Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021.

Quote to remember

“Either the largest companies in the world will gobble up a larger share of profits than has ever occurred in the U.S., or the average stock will perform much better than the S&P 500 in the years ahead, as the excessive outperformance of these mega cap stocks reverts, as it has in every past instance.”

The full answer · about 3 min

Illumina drove down the cost of sequencing an entire human genome from over $100,000 a decade ago down to just $600 with its NovaSeq 6000 high-end instrument, representing a 99% reduction in cost from 2010 to 2021. Despite this massive cost reduction, Illumina's revenue actually increased from $1 billion to $4.5 billion because applications and volumes of gene sequencing exploded higher, enabled by the greater affordability.

Key facts

  • S&P 500 returned 15.3% in first half of 2024; Ensemble Capital strategy returned 8%
  • Average stock in S&P 500 up only 5% in first half of 2024
  • Magnificent Seven stocks up 94.9% over five-quarter period versus 16.2% for average stock
  • NVIDIA up 345% over past five quarters; up 2,926% over past five years versus S&P 500 up 101%
  • Five largest companies in S&P 500 make up 25% of entire index—most intense concentration in at least half a century

People, companies and topics mentioned

Ensemble CapitalIntrinsic InvestingS&P 500Magnificent SevenNVIDIATeslaAmazonApple

More answers from this episode

 ·  All answers from Intrinsic Investing →
—
—
0:00
0:00